211 related articles for article (PubMed ID: 1981869)
1. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.
Wadworth AN; Heel RC
Drugs; 1990 Dec; 40(6):863-79. PubMed ID: 1981869
[TBL] [Abstract][Full Text] [Related]
2. [Remoxipride, a selective antagonist of dopamine D2 receptors, in the treatment of delusional psychoses].
Lewander T; Westerberg SE; Ogren SO; Von Bahr C; Köhler C
Encephale; 1990; 16(2):153-7. PubMed ID: 1972054
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
4. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Ogren SO; Hall H; Köhler C; Magnusson O; Lindbom LO; Angeby K; Florvall L
Eur J Pharmacol; 1984 Jul; 102(3-4):459-74. PubMed ID: 6149133
[TBL] [Abstract][Full Text] [Related]
5. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
Gerlach J; Casey DE
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):103-12. PubMed ID: 1967845
[TBL] [Abstract][Full Text] [Related]
6. Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme.
Lewander T; Westerbergh SE; Morrison D
Acta Psychiatr Scand Suppl; 1990; 358():92-8. PubMed ID: 1978500
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical properties of the atypical antipsychotic drug remoxipride.
Lewander T
Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():269A-270A. PubMed ID: 1354034
[No Abstract] [Full Text] [Related]
8. Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison.
Deo R; Soni S; Rastogi SC; Levine S; Plant I; Edwards JG; Mitchell M; Chanas A
Acta Psychiatr Scand Suppl; 1990; 358():120-4. PubMed ID: 1978470
[TBL] [Abstract][Full Text] [Related]
9. Biochemical pharmacology of the atypical neuroleptic remoxipride.
Köhler C; Hall H; Magnusson O; Lewander T; Gustafsson K
Acta Psychiatr Scand Suppl; 1990; 358():27-36. PubMed ID: 1978484
[TBL] [Abstract][Full Text] [Related]
10. A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia.
den Boer JA; Ravelli DP; Huisman J; Ohrvik J; Verhoeven WM; Westenberg HG
Acta Psychiatr Scand Suppl; 1990; 358():108-10. PubMed ID: 1978468
[TBL] [Abstract][Full Text] [Related]
11. Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group.
Awad AG; Lapierre YD; Jostell KG
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):769-77. PubMed ID: 2149882
[TBL] [Abstract][Full Text] [Related]
12. Neuropharmacological and behavioural properties of remoxipride in the rat.
Ogren SO; Florvall L; Hall H; Magnusson O; Angeby-Möller K
Acta Psychiatr Scand Suppl; 1990; 358():21-6. PubMed ID: 1978483
[TBL] [Abstract][Full Text] [Related]
13. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.
Nadal R
CNS Drug Rev; 2001; 7(3):265-82. PubMed ID: 11607043
[TBL] [Abstract][Full Text] [Related]
15. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
16. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.
den Boer JA; Westenberg HG
Psychopharmacol Bull; 1990; 26(1):99-107. PubMed ID: 1973547
[TBL] [Abstract][Full Text] [Related]
17. An open multicentre study of the treatment of florid schizophrenia with remoxipride.
McCreadie RG; Morrison D; Eccleston D; Gall RG; Loudon J; Mitchell MJ
Acta Psychiatr Scand; 1985 Aug; 72(2):139-43. PubMed ID: 2864790
[TBL] [Abstract][Full Text] [Related]
18. Experiences of long-term treatment with remoxipride: efficacy and tolerability.
Wålinder J; Holm AC
Acta Psychiatr Scand Suppl; 1990; 358():158-63. PubMed ID: 1978477
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of antipsychotic agents. Do newer agents offer advantages?
Owens DG
Drugs; 1996 Jun; 51(6):895-930. PubMed ID: 8736614
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity.
Lund Laursen A; Gerlach J
Acta Psychiatr Scand; 1986 Jan; 73(1):17-21. PubMed ID: 2938421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
